Allspring Global Investments
CERE

Allspring Global Investments’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Allspring Global Investments’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-457
Closed -$14.4K – 2970
2022
Q4 		$14.4K Sell
457
-11
-2% -$310 ﹤0.01% 2651
2022
Q3 		$13K Buy
468
+301
+180% +$8.96K ﹤0.01% 2698
2022
Q2 		$4K Hold
167
– – ﹤0.01% 2627
2022
Q1 		$5K Buy
+167
New +$4.88K ﹤0.01% 2984

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Allspring Global Investments's CERE Position: Q1 2023 in Review

Allspring Global Investments sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2023, closing a stake of 457 shares — an estimated $14.4K sold.

Allspring Global Investments first reported a position in CERE in Q1 2022 and held it in 4 quarters. The position peaked at $14.4K in Q4 2022. 119 funds tracked by Wall St. Rank hold CERE as of Q1 2023.

  • Allspring Global Investments reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Allspring Global Investments sold 457 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2023, an estimated $14.4K.
  • Allspring Global Investments first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Allspring Global Investments's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $14.4K in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2023.

Based on Allspring Global Investments's 13F filing for Q1 2023, filed 13 Apr 2023.